• Are we there yet? more
  • Are Web Development Methods Too Difficult To Use? more
  • Are well‐intended Buddhist practices an under‐appreciated threat to global aquatic biodiversity? more
  • Are women's expectations and preferences for intrapartum care affected by the model of care on offer? more
  • Are you anonymous? Social-psychological processes of hacking groups more
  • Are you ready for your child, the 3D printing genius? more
  • Are You There more
  • Are You There: Material and Immaterial more
  • Are You There: the relationship between film and screen more
  • Are You There? more
  • ARElight: Context Sampling of Large Texts for Deep Learning Relation Extraction more
  • ARFDNet: An efficient activity recognition & fall detection system using latent feature pooling more
  • Arm motion monitoring and recovery assessment device more
  • Arming the citizen-consumer: the invention of ‘media literacy’ within UK communications policy more
  • Arnold, Doris Grace (1904-1969), radio presenter and producer more
  • Arsenic in the bengal delta plain: Geochemical complications and potential mitigation option more
  • Arsenic mobilization in the aquifers of three physiographic settings of West Bengal, India: understanding geogenic and anthropogenic influences. more
  • Art in corporate governance: A Deweyan perspective on board experience more
  • Art in corporate governance: A Deweyan perspective on board experience more
  • Art in Motion: current research in screendance more
  • Art Park Space more
  • ART: Ankle Recovery Trial Protocol v 1.6 more
  • ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR) more
  • ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). more
  • ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer more

Previous Next